BHC(SH:600721) Sou Hu Cai Jing·2025-04-07 19:06Group 1 - The core viewpoint of the articles highlights the performance and valuation of Baihua Pharmaceutical, which closed at 6.64 yuan, down 10.03%, with a rolling PE ratio of 61.49 times and a total market value of 2.551 billion yuan [1] - Baihua Pharmaceutical ranks 33rd in the medical services industry, which has an average PE ratio of 45.72 times and a median of 41.83 times [1][2] - As of February 28, 2025, Baihua Pharmaceutical had 32,430 shareholders, a decrease of 2,405 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Group 2 - The main business of Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. includes early drug discovery and screening, drug CMC development, clinical trials, registration applications, BE/PK bio-sample analysis, and pharmaceutical testing services [1] - The latest financial results for the year 2024 show that the company achieved an operating income of 386 million yuan, a year-on-year increase of 4.46%, and a net profit of 41.479 million yuan, a year-on-year increase of 219.75%, with a gross profit margin of 51.19% [1]